<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>KETOROLAC TROMETHAMINE- ketorolac tromethamine injection, solution </strong><br>Sagent Pharmaceuticals<br></p></div>
<h1>Ketorolac Tromethamine Injection, USP
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1"></a><p></p>
<p class="First">SAGENT™<br>Rx only
</p>
</div>
<div class="Warning">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>WARNING
</h1>
<p class="First">Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the short-term (up to 5 days in adults), management of moderately severe <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span> that requires <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> at the opioid level. Oral ketorolac tromethamine is indicated only as continuation treatment following IV or IM dosing of ketorolac tromethamine, if necessary. The total combined duration of use of oral ketorolac tromethamine and ketorolac tromethamine injection should not exceed 5 days.
</p>
<p>Ketorolac tromethamine is not indicated for use in pediatric patients and it is NOT indicated for minor or chronic painful conditions. Increasing the dose of ketorolac tromethamine beyond the label recommendations will not provide better efficacy but will increase the risk of developing serious adverse events.
</p>
<p><span class="Bold">GASTROINTESTINAL RISK </span></p>
<ul class="Disc"><li>Ketorolac tromethamine can cause <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcers</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> and/or perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Therefore, ketorolac tromethamine is CONTRAINDICATED in patients with active <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span>, in patients with recent <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> or perforation, and in patients with a history of <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span> or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. Elderly patients are at greater risk for serious gastrointestinal events (see <span class="Bold"><a href="#s25">WARNINGS</a></span>).
</li></ul>
<p><span class="Bold">CARDIOVASCULAR THROMBOTIC EVENTS</span></p>
<ul class="Disc">
<li>Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. This risk may occur early in treatment and may increase with duration of use (see <span class="Bold"><a href="#s25">WARNINGS</a></span> and <span class="Bold"><a href="#s38">PRECAUTIONS</a></span>).
</li>
<li>Ketorolac tromethamine is CONTRAINDICATED in the setting of coronary artery bypass graft (CABG) surgery (see <span class="Bold"><a href="#s24">CONTRAINDICATIONS</a></span> and <span class="Bold"><a href="#s25">WARNINGS</a></span>).
</li>
</ul>
<p><span class="Bold">RENAL RISK </span></p>
<ul class="Disc"><li>Ketorolac tromethamine is CONTRAINDICATED in patients with advanced <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and in patients at risk for <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> due to <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span> (see <span class="Bold"><a href="#s25">WARNINGS</a></span>).
</li></ul>
<p><span class="Bold">RISK OF <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">BLEEDING</span> </span></p>
<ul class="Disc"><li>Ketorolac tromethamine inhibits platelet function and is, therefore, CONTRAINDICATED in patients with suspected or confirmed cerebrovascular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, patients with <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">hemorrhagic diathesis</span>, incomplete hemostasis and those at high risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (see <span class="Bold"><a href="#s25">WARNINGS</a></span> and <span class="Bold"><a href="#s38">PRECAUTIONS</a></span>).
</li></ul>
<p><span class="Bold">Ketorolac tromethamine is CONTRAINDICATED as <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> analgesic before any major surgery.</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span> </span></p>
<ul class="Disc"><li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>, ranging from <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> to <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>, have occurred and appropriate counteractive measures must be available when administering the first dose of ketorolac tromethamine injection (see <span class="Bold"><a href="#s24">CONTRAINDICATIONS</a></span> and <span class="Bold"><a href="#s25">WARNINGS</a></span>). Ketorolac tromethamine is CONTRAINDICATED in patients with previously demonstrated <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to ketorolac tromethamine or allergic manifestations to aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs).
</li></ul>
<p><span class="Bold">INTRATHECAL OR EPIDURAL ADMINISTRATION </span></p>
<ul class="Disc"><li>Ketorolac tromethamine is CONTRAINDICATED for intrathecal or epidural administration due to its alcohol content.
</li></ul>
<p><span class="Bold">RISK DURING LABOR AND DELIVERY </span></p>
<ul class="Disc"><li>The use of ketorolac tromethamine in labor and delivery is CONTRAINDICATED because it may adversely affect fetal circulation and inhibit uterine contractions.
</li></ul>
<p><span class="Bold">CONCOMITANT USE WITH NSAIDS </span></p>
<ul class="Disc"><li>Ketorolac tromethamine is CONTRAINDICATED in patients currently receiving aspirin or NSAIDs because of the cumulative risk of inducing serious NSAID-related side effects.
</li></ul>
<p><span class="Bold">SPECIAL POPULATIONS </span></p>
<ul class="Disc"><li>Dosage should be adjusted for patients 65 years or older, for patients under 50 kg (110 lbs.) of body weight (see <span class="Bold"><a href="#s73">DOSAGE AND ADMINISTRATION</a></span>) and for patients with moderately elevated serum creatinine (see <span class="Bold"><a href="#s25">WARNINGS</a></span>). Doses of ketorolac tromethamine injection are not to exceed 60 mg (total dose per day) in these patients.
</li></ul>
<p><span class="Bold">DOSAGE AND ADMINISTRATION</span></p>
<p><span class="Bold">Ketorolac Tromethamine Tablets</span></p>
<ul class="Disc">
<li>Ketorolac tromethamine tablets are indicated only as continuation therapy to ketorolac tromethamine injection, and the combined duration of use of ketorolac tromethamine injection and ketorolac tromethamine tablets is not to exceed 5 (five) days, because of the increased risk of serious adverse events.
</li>
<li>The recommended total daily dose of ketorolac tromethamine tablets (maximum 40 mg) is significantly lower than for ketorolac tromethamine injection (maximum 120 mg) (see <span class="Bold"><a href="#s73">DOSAGE AND ADMINISTRATION</a></span>).
</li>
</ul>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s3"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION
</h1>
<p class="First">Ketorolac tromethamine is a member of the pyrrolo-pyrrole group of nonsteroidal anti-inflammatory drugs (NSAIDs). The chemical name for ketorolac tromethamine is (±)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1), and the structural formula is below:
</p>
<div class="Figure">
<a name="f01"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=62591551-a644-4b2c-a0de-982e906fabc3&amp;name=ket06-0001-01.jpg">
</div>
<p>Ketorolac tromethamine, USP is a white to off-white, crystalline powder and is a racemic mixture of [-]S and [+]R ketorolac tromethamine. Ketorolac tromethamine may exist in three crystal forms. All forms are equally soluble in water. Ketorolac tromethamine has a pK<span class="Sub">a</span> of 3.5 and an n-octanol/water partition coefficient of 0.26. The molecular weight of ketorolac tromethamine is 376.40.
</p>
<p>Ketorolac Tromethamine Injection, USP is available for intravenous (IV) or intramuscular (IM) administration as: 15 mg in 1 mL (1.5%) and 30 mg in 1 mL (3%) in sterile solution and 60 mg in 2 mL (3%) of ketorolac tromethamine in sterile solution is available for IM administration only. The solutions contain 10% (w/v) alcohol, USP, and 6.68 mg, 4.35 mg and 8.70 mg respectively, of sodium chloride in sterile water. The pH range is 6.9 to 7.9 and is adjusted with sodium hydroxide and/or hydrochloric acid. The sterile solutions are clear and slightly yellow in color.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s4"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43681-6">
<a name="s5"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacodynamics
</h2>
<p class="First">Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits analgesic activity in animal models. The mechanism of action of ketorolac, like that of other NSAIDs, is not completely understood but may be related to prostaglandin synthetase inhibition. The biological activity of ketorolac tromethamine is associated with the S-form. Ketorolac tromethamine possesses no sedative or anxiolytic properties.
</p>
<p>The peak <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> of ketorolac tromethamine occurs within 2 to 3 hours and is not statistically significantly different over the recommended dosage range of ketorolac tromethamine. The greatest difference between large and small doses of ketorolac tromethamine is in the duration of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>.
</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s6"></a><a name="section-3.2"></a><p></p>
<h2>Pharmacokinetics
</h2>
<p class="First">Ketorolac tromethamine is a racemic mixture of [-]S and [+]R-enantiomeric forms, with the S-form having analgesic activity.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-3.3"></a><p></p>
<h2>Comparison of IV, IM and Oral Pharmacokinetics: 
</h2>
<p class="First">The pharmacokinetics of ketorolac tromethamine, following IV, IM and oral doses of ketorolac tromethamine are compared in <a href="#t1">Table 1</a>. In adults, the extent of bioavailability following administration of the ORAL and IM forms of ketorolac tromethamine was equal to that following an IV bolus.
</p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1 Table of Approximate Average Pharmacokinetic Parameters (Mean ± SD) Following Oral, Intramuscular and Intravenous Doses of Ketorolac Tromethamine
</span></caption>
<col align="left" width="17.726%">
<col align="left" width="11.484%">
<col align="left" width="11.470%">
<col align="left" width="11.456%">
<col align="left" width="11.456%">
<col align="left" width="18.026%">
<col align="left" width="18.383%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule Toprule" align="center" rowspan="2" valign="top">
<span class="Bold">Pharmacokinetic</span><br><span class="Bold">Parameters (units)</span>
</th>
<th class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Oral</span><span class="Sup">*</span>
</th>
<th class="Botrule Rrule Toprule" align="center" colspan="3" valign="top">
<span class="Bold">Intramuscular</span><span class="Sup">†</span>
</th>
<th class="Botrule Rrule Toprule" align="center" colspan="2" valign="top">
<span class="Bold">Intravenous Bolus</span><span class="Sup">‡</span>
</th>
</tr>
<tr>
<th class="Botrule Rrule" align="center" valign="top">10 mg
</th>
<th class="Botrule Rrule" align="center" valign="top">15 mg
</th>
<th class="Botrule Rrule" align="center" valign="top">30 mg
</th>
<th class="Botrule Rrule" align="center" valign="top">60 mg
</th>
<th class="Botrule Rrule" align="center" valign="top">15 mg
</th>
<th class="Botrule Rrule" align="center" valign="top">30 mg
</th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold">Bioavailability (extent)</span></th>
<th class="Botrule Rrule" align="center" colspan="6" valign="top">100%
</th>
</tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="7" valign="top"><p class="First Footnote">% Dose metabolized = &lt;50 
</p></td></tr>
<tr><td align="left" colspan="7" valign="top"><p class="First Footnote">% Dose excreted in feces = 6
</p></td></tr>
<tr><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">1</span>Time-to-peak plasma concentration
</p></td></tr>
<tr><td align="left" colspan="7" valign="top"><p class="First Footnote">% Dose excreted in urine = 91
</p></td></tr>
<tr><td align="left" colspan="7" valign="top"><p class="First Footnote">% Plasma protein binding = 99
</p></td></tr>
<tr><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">2</span>Peak plasma concentration
</p></td></tr>
<tr><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">*</span>Derived from PO pharmacokinetic studies in 77 normal fasted volunteers
</p></td></tr>
<tr><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">3</span>Trough plasma concentration
</p></td></tr>
<tr><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">†</span>Derived from IM pharmacokinetic studies in 54 normal volunteers
</p></td></tr>
<tr><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">4</span>Average plasma concentration
</p></td></tr>
<tr><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">‡</span>Derived from IV pharmacokinetic studies in 24 normal volunteers
</p></td></tr>
<tr><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">5</span>Volume of distribution
</p></td></tr>
<tr><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">§</span> Mean value was simulated from observed plasma concentration data and standard deviation was simulated from percent coefficient of variation for observed C<span class="Sub">max</span> and T<span class="Sub">max</span> data
</p></td></tr>
<tr class="Last"><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">||</span>Not applicable because 60 mg is only recommended as a single dose
</p></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" valign="top">T<span class="Sub">max</span><span class="Sup">1</span> (min)
</td>
<td class="Botrule Rrule" align="center" valign="top">44±34
</td>
<td class="Botrule Rrule" align="center" valign="top">33±21<span class="Sup">§</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">44±29
</td>
<td class="Botrule Rrule" align="center" valign="top">33±21<span class="Sup">§</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1.1±0.7<span class="Sup">§</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2.9±1.8
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">C<span class="Sub">max</span><span class="Sup">2</span> (mcg/mL)<br>[single-dose]
</td>
<td class="Botrule Rrule" align="center" valign="top">0.87±0.22
</td>
<td class="Botrule Rrule" align="center" valign="top">1.14±0.32<span class="Sup">§</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2.42±0.68
</td>
<td class="Botrule Rrule" align="center" valign="top">4.55±1.27<span class="Sup">§</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2.47±0.51<span class="Sup">§</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">4.65±0.96
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">C<span class="Sub">max</span>(mcg/mL)<br>[steady state qid]
</td>
<td class="Botrule Rrule" align="center" valign="top">1.05±0.26<span class="Sup">§</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1.56±0.44<span class="Sup">§</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">3.11±0.87<span class="Sup">§</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">N/A<span class="Sup">||</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">3.09±1.17<span class="Sup">§</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">6.85±2.61
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">C<span class="Sub">min</span><span class="Sup">3</span> (mcg/mL)<br>[steady state qid]
</td>
<td class="Botrule Rrule" align="center" valign="top">0.29±0.07<span class="Sup">§</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">0.47±0.13<span class="Sup">§</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">0.93±0.26<span class="Sup">§</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">N/A
</td>
<td class="Botrule Rrule" align="center" valign="top">0.61±0.21<span class="Sup">§</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1.04±0.35
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">C<span class="Sub">avg</span><span class="Sup">4</span> (mcg/mL)<br>[steady state qid]
</td>
<td class="Botrule Rrule" align="center" valign="top">0.59±0.20<span class="Sup">§</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">0.94±0.29<span class="Sup">§</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1.88±0.59<span class="Sup">§</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">N/A
</td>
<td class="Botrule Rrule" align="center" valign="top">1.09±0.30<span class="Sup">§</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">2.17±0.59
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Vβ<span class="Sup">5</span> (L/kg)
</td>
<td class="Botrule Rrule" align="center" colspan="4" valign="top">0.175±0.039
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">0.210±0.044
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-3.4"></a><p></p>
<h2>Linear Kinetics
</h2>
<p class="First">In adults, following administration of single ORAL, IM or IV doses of ketorolac tromethamine in the recommended dosage ranges, the clearance of the racemate does not change. This implies that the pharmacokinetics of ketorolac tromethamine in adults, following single or multiple IM, IV or recommended oral doses of ketorolac tromethamine, are linear. At the higher recommended doses, there is a proportional increase in the concentrations of free and bound racemate.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-3.5"></a><p></p>
<h2>Distribution
</h2>
<p class="First">The mean apparent volume (Vβ) of ketorolac tromethamine following complete distribution was approximately 13 liters. This parameter was determined from single-dose data. The ketorolac tromethamine racemate has been shown to be highly protein bound (99%). Nevertheless, plasma concentrations as high as 10 mcg/mL will only occupy approximately 5% of the albumin binding sites. Thus, the unbound fraction for each enantiomer will be constant over the therapeutic range. A decrease in serum albumin, however, will result in increased free drug concentrations.
</p>
<p>Ketorolac tromethamine is excreted in human milk (see <span class="Bold"><a href="#s65">PRECAUTIONS: Nursing mothers</a></span>).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-3.6"></a><p></p>
<h2>Metabolism
</h2>
<p class="First">Ketorolac tromethamine is largely metabolized in the liver. The metabolic products are hydroxylated and conjugated forms of the parent drug. The products of metabolism, and some unchanged drug, are excreted in the urine.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-3.7"></a><p></p>
<h2>Excretion
</h2>
<p class="First">The principal route of elimination of ketorolac and its metabolites is renal. About 92% of a given dose is found in the urine, approximately 40% as metabolites and 60% as unchanged ketorolac. Approximately 6% of a dose is excreted in the feces. A single-dose study with 10 mg ketorolac tromethamine (n=9) demonstrated that the S-enantiomer is cleared approximately two times faster than the R-enantiomer and that the clearance was independent of the route of administration. This means that the ratio of S/R plasma concentrations decreases with time after each dose. There is little or no inversion of the R- to S- form in humans. The clearance of the racemate in normal subjects, elderly individuals and in hepatically and renally impaired patients is outlined in <a href="#t2">Table 2</a> (see <span class="Bold"><a href="#s13">CLINICAL PHARMACOLOGY: Kinetics in Special Populations</a></span>).
</p>
<p>The half-life of the ketorolac tromethamine S-enantiomer was approximately 2.5 hours (SD ± 0.4) compared with 5 hours (SD ± 1.7) for the R-enantiomer. In other studies, the half-life for the racemate has been reported to lie within the range of 5 to 6 hours.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-3.7.1"></a><p></p>
<h3>Accumulation
</h3>
<p class="First">Ketorolac tromethamine administered as an IV bolus, every 6 hours for 5 days to healthy subjects (n = 13), showed no significant difference in C<span class="Sub">max</span> on Day 1 and Day 5. Trough levels averaged 0.29 mcg/mL (SD ± 0.13) on Day 1 and 0.55 mcg/mL (SD ± 0.23) on Day 6. Steady state was approached after the fourth dose.
</p>
<p>Accumulation of ketorolac tromethamine has not been studied in special populations (geriatric, pediatric, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> patients).
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-3.8"></a><p></p>
<h2>Kinetics in Special Populations
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-3.8.1"></a><p></p>
<h3>Geriatric Patients
</h3>
<p class="First">Based on single-dose data only, the half-life of the ketorolac tromethamine racemate increased from 5 to 7 hours in the elderly (65 to 78 years) compared with young healthy volunteers (24 to 35 years) (see <span class="Bold"><a href="#t2">Table 2</a></span>). There was little difference in the C<span class="Sub">max</span> for the two groups (elderly, 2.52 mcg/mL ± 0.77; young, 2.99 mcg/mL ± 1.03) (see <span class="Bold"><a href="#s67">PRECAUTIONS: Geriatric use</a></span>).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-3.8.2"></a><p></p>
<h3>Pediatric Patients
</h3>
<p class="First">Limited information is available regarding the pharmacokinetics of dosing of ketorolac tromethamine in the pediatric population. Following a single intravenous bolus dose of 0.5 mg/kg in 10 children 4 to 8 years old, the half-life was 5.8 ± 1.6 hours, the average clearance was 0.042 ± 0.01 L/hr/kg, the volume of distribution during the terminal phase (Vβ) was 0.34 ± 0.12 L/kg and the volume of distribution at steady state (Vss) was 0.26± 0.08 L/kg. The volume of distribution and clearance of ketorolac in pediatric patients was higher than those observed in adult subjects (see <span class="Bold"><a href="#t1">Table 1</a></span>). There are no pharmacokinetic data available for administration of ketorolac tromethamine by the IM route in pediatric patients.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-3.8.3"></a><p></p>
<h3>Renally Insufficiency
</h3>
<p class="First">Based on single-dose data only, the mean half-life of ketorolac tromethamine in renally impaired patients is between 6 and 19 hours, and is dependent on the extent of the impairment. There is poor correlation between creatinine clearance and total ketorolac tromethamine clearance in the elderly and populations with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (r = 0.5).
</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, the AUC∞ of each enantiomer increased by approximately 100% compared with healthy volunteers. The volume of distribution doubles for the S-enantiomer and increases by 1/5th for the R-enantiomer. The increase in volume of distribution of ketorolac tromethamine implies an increase in unbound fraction.
</p>
<p>The AUC∞-ratio of the ketorolac tromethamine enantiomers in healthy subjects and patients remained similar, indicating there was no selective excretion of either enantiomer in patients compared to healthy subjects (see <span class="Bold"><a href="#s29">WARNINGS: Renal Effects</a></span>).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-3.8.4"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span>
</h3>
<p class="First">There was no significant difference in estimates of half-life, AUC∞ and C<span class="Sub">max</span> in 7 patients with liver disease compared to healthy volunteers (see <span class="Bold"><a href="#s40">PRECAUTIONS: Hepatic Effects</a></span> and <span class="Bold"><a href="#t2">Table 2</a></span>).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-3.8.5"></a><p></p>
<h3>Race
</h3>
<p class="First">Pharmacokinetic differences due to race have not been identified.
</p>
<a name="t2"></a><table width="100%">
<caption><span>Table 2 The Influence of Age, Liver and Kidney Function, on the Clearance and Terminal Half-life of Ketorolac Tromethamine (IM<span class="Sup">1</span> and ORAL<span class="Sup">2</span>) in Adult Populations
</span></caption>
<col align="left" width="25.382%">
<col align="left" width="22.497%">
<col align="left" width="10%">
<col align="left" width="13.255%">
<col align="left" width="1.771%">
<col align="left" width="22.083%">
<col align="left" width="14.127%">
<tfoot>
<tr class="First"><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">1</span>Estimated from 30 mg single IM doses of ketorolac tromethamine
</p></td></tr>
<tr><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">2</span>Estimated from 10 mg single oral doses of ketorolac tromethamine
</p></td></tr>
<tr class="Last"><td align="left" colspan="7" valign="top"><p class="First Footnote"><span class="Sup">3</span>Liters/hours/kilogram
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="4" valign="top">
<span class="Bold">Total Clearance [in L/h/kg]</span><span class="Bold"><span class="Sup">3</span></span>
</td>
<td class="Botrule Rrule Toprule" align="center" colspan="2" valign="top"><span class="Bold">Terminal Half-life [in hours]</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><span class="Bold">Type of Subjects</span></td>
<td class="Botrule" align="center" valign="top">
<span class="Bold">IM</span><br><span class="Bold">Mean (range)</span>
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">
<span class="Bold">ORAL</span><br><span class="Bold">Mean (range)</span>
</td>
<td class="Botrule" align="center" colspan="2" valign="top">
<span class="Bold">IM</span><br><span class="Bold">Mean (range)</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">
<span class="Bold">ORAL</span><br><span class="Bold">Mean (range)</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">Normal Subjects
</td>
<td align="center" valign="top">0.023
</td>
<td class="Rrule" align="center" colspan="2" valign="top">0.025
</td>
<td align="center" colspan="2" valign="top">5.3
</td>
<td class="Rrule" align="center" valign="top">5.3
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">IM (n=54)<br>mean age=32, range=18 to 60
</td>
<td align="center" valign="top">(0.010 to 0.046)
</td>
<td class="Rrule" align="center" colspan="2" valign="top">(0.013 to 0.050)
</td>
<td align="center" colspan="2" valign="top">(3.5 to 9.2)
</td>
<td class="Rrule" align="center" valign="top">(2.4 to 9.0)
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">Oral (n=77)
</td>
<td align="center" valign="top"></td>
<td class="Rrule" align="center" colspan="2" valign="top"></td>
<td align="center" colspan="2" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">mean age=32, range=20 to 60
</td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"></td>
<td class="Botrule" align="center" colspan="2" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">Healthy Elderly Subjects<br>IM (n=13), Oral (n=12)<br>mean age=72, range=65 to 78
</td>
<td class="Botrule" align="center" valign="top">0.019<br>(0.013 to 0.034)
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">0.024<br>(0.018 to 0.034)
</td>
<td class="Botrule" align="center" colspan="2" valign="top">7.0<br>(4.7 to 8.6)
</td>
<td class="Botrule Rrule" align="center" valign="top">6.1<br>(4.3 to 7.6)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">Patients with Hepatic Dysfunction<br>IM and Oral (n=7)<br>mean age=51, range=43 to 64
</td>
<td class="Botrule" align="center" valign="top">0.029<br>(0.013 to 0.066)
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">0.033<br>(0.019 to 0.051)
</td>
<td class="Botrule" align="center" colspan="2" valign="top">5.4<br>(2.2 to 6.9)
</td>
<td class="Botrule Rrule" align="center" valign="top">4.5<br>(1.6 to 7.6)
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span><br>IM (n=25), Oral (n=9)<br>serum creatinine=1.9 to 5.0 mg/dL<br>mean age (IM)=54, range=35 to 71<br>mean age (Oral)=57, range=39 to 70
</td>
<td class="Botrule" align="center" valign="top">0.015<br>(0.005 to 0.043)
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">0.016<br>(0.007 to 0.052)
</td>
<td class="Botrule" align="center" colspan="2" valign="top">10.3<br>(5.9 to 19.2)
</td>
<td class="Botrule Rrule" align="center" valign="top">10.8<br>(3.4 to 18.9)
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">Renal Dialysis Patients<br>IM and Oral (n=9)<br>mean age=40, range=27 to 63
</td>
<td class="Botrule" align="center" valign="top">0.016<br>(0.003 to 0.036)
</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">----
</td>
<td class="Botrule" align="center" colspan="2" valign="top">13.6<br>(8.0 to 39.1)
</td>
<td class="Botrule Rrule" align="center" valign="top">----
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-3.9"></a><p></p>
<h2>IV Administration
</h2>
<p class="First">In normal adult subjects (n=37), the total clearance of 30 mg IV-administered ketorolac tromethamine was 0.030 (0.017 to 0.051) L/h/kg. The terminal half-life was 5.6 (4.0 to 7.9) hours (see <span class="Bold"><a href="#s13">Kinetics in Special Populations</a></span> for use of IV dosing of ketorolac tromethamine in pediatric patients).
</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s20"></a><a name="section-3.10"></a><p></p>
<h2>Clinical Studies
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-3.10.1"></a><p></p>
<h3>Adult Patients
</h3>
<p class="First">In a postoperative study, where all patients received morphine by a PCA device, patients treated with ketorolac tromethamine IV as fixed intermittent boluses (e.g., 30 mg initial dose followed by 15 mg q3h), required significantly less morphine (26%) than the placebo group. <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span> was significantly superior, at various postdosing <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> assessment times, in the patients receiving ketorolac tromethamine IV plus PCA morphine as compared to patients receiving PCA-administered morphine alone.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s22"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE
</h1>
<p class="First">Carefully consider the potential benefits and risks ketorolac tromethamine injection and other treatment options before deciding to use ketorolac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see <span class="Bold"><a href="#s25">WARNINGS</a></span>).
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-4.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">Acute Pain</span> in Adult Patients
</h2>
<p class="First">Ketorolac tromethamine injection is indicated for the short-term (≤5 days) management of moderately severe <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span> that requires <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> at the opioid level, usually in a postoperative setting. Therapy should always be initiated with IV or IM dosing of ketorolac tromethamine injection, and oral ketorolac tromethamine is to be used only as continuation treatment, if necessary.
</p>
<p>The total combined duration of use of ketorolac tromethamine injection and oral ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see <span class="Bold"><a href="#s25">WARNINGS</a></span>, <span class="Bold"><a href="#s38">PRECAUTIONS</a></span>, <span class="Bold"><a href="#s73">DOSAGE AND ADMINISTRATION</a></span>, and <span class="Bold"><a href="#s68">ADVERSE REACTIONS</a></span>). Patients should be switched to alternative analgesics as soon as possible, but ketorolac tromethamine therapy is not to exceed 5 days.
</p>
<p>Ketorolac tromethamine injection has been used concomitantly with morphine and meperidine and has shown an opioidsparing effect. For breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, it is recommended to supplement the lower end of the ketorolac tromethamine injection dosage range with low doses of narcotics prn, unless otherwise contraindicated. Ketorolac tromethamine injection and narcotics should not be administered in the same syringe (see <span class="Bold"><a href="#s80">DOSAGE AND ADMINISTRATION: Pharmaceutical Information for Ketorolac Tromethamine Injection</a></span>).
</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s24"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS 
</h1>
<p class="First"><span class="Bold">(See also <a href="#s2">Boxed WARNING</a>)</span></p>
<p>Ketorolac tromethamine injection is contraindicated in patients with previously demonstrated <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to ketorolac tromethamine.
</p>
<p>Ketorolac tromethamine injection is contraindicated in patients with active <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span>, in patients with recent <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> or perforation and in patients with a history of <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span> or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>.
</p>
<p>Ketorolac tromethamine injection should not be given to patients who have experienced <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients (see <span class="Bold"><a href="#s31">WARNINGS: <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></a>,</span> and <span class="Bold"><a href="#s42">PRECAUTIONS: Preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></a></span>).
</p>
<p>Ketorolac tromethamine injection is contraindicated as <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> analgesic before any major surgery.
</p>
<p>Ketorolac tromethamine injection is contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see <span class="Bold"><a href="#s25">WARNINGS</a></span>).
</p>
<p>Ketorolac tromethamine injection is contraindicated in patients with advanced <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or in patients at risk for <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> due to <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span> (see <span class="Bold"><a href="#s25">WARNINGS</a></span> for correction of <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>).
</p>
<p>Ketorolac tromethamine injection is contraindicated in labor and delivery because, through its prostaglandin synthesis inhibitory effect, it may adversely affect fetal circulation and inhibit uterine contractions, thus increasing the risk of <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine hemorrhage</span>.
</p>
<p>Ketorolac tromethamine inhibits platelet function and is, therefore, contraindicated in patients with suspected or confirmed cerebrovascular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">hemorrhagic diathesis</span>, incomplete hemostasis and those at high risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (see <span class="Bold"><a href="#s25">WARNINGS</a></span> and <span class="Bold"><a href="#s38">PRECAUTIONS</a></span>).
</p>
<p>Ketorolac tromethamine injection is contraindicated in patients currently receiving asprin or NSAIDs because of the cumulative risks of inducing serious NSAID-related adverse events.
</p>
<p>The concomitant use of ketorolac tromethamine injection and probenecid is contraindicated.
</p>
<p>The concomitant use of ketorolac tromethamine injection and pentoxifylline is contraindicated.
</p>
<p>Ketorolac tromethamine injection is contraindicated for neuraxial (epidural or intrathecal) administration due to its alcohol content.
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s25"></a><a name="section-6"></a><p></p>
<h1>WARNINGS 
</h1>
<p class="First"><span class="Bold">(See also <a href="#s2">Boxed WARNING</a>)</span></p>
<p>The total combined duration of use of oral ketorolac tromethamine and IV or IM dosing of ketorolac tromethamine is not to exceed 5 days in adults. Ketorolac tromethamine injection is not indicated for use in pediatric patients.
</p>
<p>The most serious risks associated with ketorolac tromethamine are:
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s26"></a><a name="section-6.1"></a><p></p>
<h2>Gastrointestinal Effects 
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s27"></a><a name="section-6.1.1"></a><p></p>
<h3>Risk of Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation
</h3>
<p class="First">Ketorolac tromethamine is contraindicated in patients with previously documented <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcers</span> and/or GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Ketorolac tromethamine can cause serious gastrointestinal (GI) adverse events including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration and perforation, of the stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with ketorolac tromethamine.
</p>
<p>Only one in five patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic. Minor upper gastrointestinal problems, such as <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, are common and may also occur at any time during NSAID therapy. The incidence and severity of gastrointestinal complications increases with increasing dose of, and duration of treatment with, ketorolac tromethamine. Do not use ketorolac tromethamine for more than five days. However, even short-term therapy is not without risk. In addition to past history of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease, other factors that increase the risk for GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients treated with NSAIDs include concomitant use of oral corticosteroids, or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. Most spontaneous reports of fatal GI events are in elderly or debilitated patients and therefore, special care should be taken in treating this population.
</p>
<p><span class="Bold">To minimize the potential risk for an adverse GI event, the lowest effective dose should be used for the shortest possible duration.</span> Patients and physicians should remain alert for signs and symptoms of GI ulceration and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during NSAID therapy and promptly initiate additional evaluation and treatment if a serious GI adverse event is suspected. This should include discontinuation of ketorolac tromethamine until a serious GI adverse event is ruled out. For high risk patients, alternate therapies that do not involve NSAIDs should be considered. NSAIDs should be given with care to patients with a history of <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span> (<span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, Crohn's disease) as their condition may be exacerbated.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s28"></a><a name="section-6.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span>
</h2>
<p class="First">Because prostaglandins play an important role in hemostasis and NSAIDs affect platelet aggregation as well, use of ketorolac tromethamine in patients who have <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorders</span> should be undertaken very cautiously, and those patients should be carefully monitored. Patients on therapeutic doses of anticoagulants (e.g., heparin or dicumarol derivatives) have an increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> complications if given ketorolac tromethamine concurrently; therefore, physicians should administer such concomitant therapy only extremely cautiously. The concurrent use of ketorolac tromethamine and therapy that affects hemostasis, including <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> low-dose heparin (2,500 to 5,000 units q12h), warfarin and dextrans have not been studied extensively, but may also be associated with an increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Until data from such studies are available, physicians should carefully weigh the benefits against the risks and use such concomitant therapy in these patients only extremely cautiously. Patients receiving therapy that affects hemostasis should be monitored closely.
</p>
<p>In postmarketing experience, postoperative <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> and other signs of <span class="product-label-link" type="condition" conceptid="4343234" conceptname="Wound hemorrhage">wound bleeding</span> have been reported in association with the peri-operative use of IV or IM dosing of ketorolac tromethamine. Therefore, peri-operative use of ketorolac tromethamine should be avoided and postoperative use be undertaken with caution when hemostasis is critical (see <span class="Bold"><a href="#s38">PRECAUTIONS</a></span>).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-6.3"></a><p></p>
<h2>Renal Effects
</h2>
<p class="First">Long-term administration of NSAIDs has resulted in <span class="product-label-link" type="condition" conceptid="4152839" conceptname="Acute papillary necrosis">renal papillary necrosis</span> and other <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span>. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.
</p>
<p>Ketorolac tromethamine and its metabolites are eliminated primarily by the kidneys, which, in patients with reduced creatinine clearance, will result in diminished clearance of the drug (see <span class="Bold"><a href="#s4">CLINICAL PHARMACOLOGY</a></span>). Therefore, ketorolac tromethamine should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (see <span class="Bold"><a href="#s73">DOSAGE AND ADMINISTRATION</a></span>) and such patients should be followed closely. With the use of ketorolac tromethamine, there have been reports of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> and <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-6.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span>
</h2>
<p class="First">Ketorolac tromethamine is contraindicated in patients with serum creatinine concentrations indicating advanced <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (see <span class="Bold"><a href="#s24">CONTRAINDICATIONS</a></span>). Ketorolac tromethamine should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> or a history of kidney disease because it is a potent inhibitor of prostaglandin synthesis. Because patients with underlying <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> are at increased risk of developing acute renal decompensation or failure, the risks and benefits should be assessed prior to giving ketorolac tromethamine to these patients.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s31"></a><a name="section-6.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span>
</h2>
<p class="First">As with other NSAIDs, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> may occur in patients without known prior exposure to ketorolac tromethamine. Ketorolac tromethamine should not be given to patients with the aspirin triad. This symptom complex typically occurs in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients who experience <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> with or without <span class="product-label-link" type="condition" conceptid="253788" conceptname="Nasal polyp">nasal polyps</span>, or who exhibit severe, potentially fatal <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> after taking aspirin or other NSAIDs (see <span class="Bold"><a href="#s24">CONTRAINDICATIONS</a></span> and <span class="Bold"><a href="#s42">PRECAUTIONS: Preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></a></span>). Emergency help should be sought in cases where an <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> occurs.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-6.6"></a><p></p>
<h2>Cardiovascular Effects
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-6.6.1"></a><p></p>
<h3>Cardiovascular Thrombotic Events
</h3>
<p class="First">Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, including <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI) and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. Based on available data, it is unclear that the risk for CV thrombotic events is similar for all NSAIDs.  The relative increase in serious CV thrombotic events over baseline conferred by NSAID use appears to be similar in those with and without known CV disease or risk factors for CV disease. However, patients with known CV disease or risk factors had a higher absolute incidence of excess serious CV thrombotic events, due to their increased baseline rate. Some observational studies found that this increased risk of serious CV thrombotic events began as early as the first weeks of treatment. The increase in CV thrombotic risk has been observed most consistently at higher doses.
</p>
<p>To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective dose for the shortest duration possible. Physicians and patients should remain alert for the development of such events, throughout the entire treatment course, even in the absence of previous CV symptoms. Patients should be informed about the symptoms of serious CV events and the steps to take if they occur.
</p>
<p>There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID, such as ketorolac, increases the risk of serious gastrointestinal (GI) events (see <span class="Bold"><a href="#s25">WARNINGS</a></span>).
</p>
<p><span class="Underline">Status Post Coronary Artery Bypass Graft (CABG) Surgery</span></p>
<p>Two large, controlled clinical trials of a COX-2 selective NSAID for the treatment of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the first 10 to 14 days following CABG surgery found an increased incidence of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. NSAIDs are contraindicated in the setting of CABG (see <span class="Bold"><a href="#s24">CONTRAINDICATIONS</a></span>).
</p>
<p><span class="Underline">Post-MI Patients</span></p>
<p>Observational studies conducted in the Danish National Registry have demonstrated that patients treated with NSAIDs in the post-MI period were at increased risk of reinfarction, CV-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, and all-cause mortality beginning in the first week of treatment. In this same cohort, the incidence of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in the first year post-MI was 20 per 100 person years in NSAID-treated patients compared to 12 per 100 person years in non-NSAID exposed patients. Although the absolute rate of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> declined somewhat after the first year post-MI, the increased relative risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in NSAID users persisted over at least the next four years of follow-up.
</p>
<p>Avoid the use of ketorolac tromethamine in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If ketorolac tromethamine is used in patients with a recent MI, monitor patients for signs of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">cardiac ischemia</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s34"></a><a name="section-6.7"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>
</h2>
<p class="First">NSAIDs, including ketorolac tromethamine, can lead to onset of new <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or worsening of pre-existing <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, either of which may contribute to the increased incidence of CV events. Patients taking thiazides or loop diuretics may have impaired response to these therapies when taking NSAIDs. NSAIDs, including ketorolac tromethamine, should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Blood pressure (BP) should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s35"></a><a name="section-6.8"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>
</h2>
<p class="First">The Coxib and traditional NSAID Trialists' Collaboration meta-analysis of randomized controlled trials demonstrated an approximately two-fold increase in hospitalizations for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> in COX-2 selective-treated patients and nonselective NSAID-treated patients compared to placebo-treated patients. In a Danish National Registry study of patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, NSAID use increased the risk of MI, hospitalization for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.
</p>
<p>Additionally, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> have been observed in some patients treated with NSAIDs. Use of ketorolac may blunt the CV effects of several therapeutic agents used to treat these medical conditions [e.g., diuretics, ACE inhibitors, or angiotensin receptor blockers (ARBs)] (see <span class="Bold"><a href="#s45">PRECAUTIONS, Drug Interactions</a></span>).
</p>
<p>Avoid the use of ketorolac tromethamine in patients with severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> unless the benefits are expected to outweigh the risk of worsening <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. If ketorolac tromethamine is used in patients with severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, monitor patients for signs of worsening <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s36"></a><a name="section-6.9"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span>
</h2>
<p class="First">NSAIDs, including ketorolac tromethamine, can cause serious skin adverse events such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span> (SJS), and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN), which can be fatal. These serious events may occur without warning. Patients should be informed about the signs and symptoms of serious skin manifestations and use of the drug should be discontinued at the first appearance of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s37"></a><a name="section-6.10"></a><p></p>
<h2>Pregnancy
</h2>
<p class="First">In late pregnancy, as with other NSAIDs, ketorolac tromethamine should be avoided because it may cause premature closure of the ductus arteriosus.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s38"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s39"></a><a name="section-7.1"></a><p></p>
<h2>General
</h2>
<p class="First">Ketorolac tromethamine cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to disease exacerbation. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids.
</p>
<p>The pharmacological activity of ketorolac tromethamine in reducing <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> may diminish the utility of this diagnostic sign in detecting complications of presumed noninfectious, painful conditions.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s40"></a><a name="section-7.2"></a><p></p>
<h2>Hepatic Effects
</h2>
<p class="First">Ketorolac tromethamine should be used with caution in patients with impaired hepatic function or a history of liver disease. Borderline elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs including ketorolac tromethamine. These laboratory abnormalities may progress, may remain unchanged, or may be transient with continuing therapy. Notable elevations of ALT or AST (approximately three or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with NSAIDs. In addition, rare cases of severe hepatic reactions, including <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> and fatal fulminant <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">liver necrosis</span> and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, some of them with fatal outcomes have been reported.
</p>
<p>A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be evaluated for evidence of the development of a more severe hepatic reaction while on therapy with ketorolac tromethamine. If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, etc.), ketorolac tromethamine should be discontinued.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s41"></a><a name="section-7.3"></a><p></p>
<h2>Hematological Effects
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> is sometimes seen in patients receiving NSAIDs, including ketorolac tromethamine. This may be due to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, occult or gross GI blood loss, or an incompletely described effect upon erythropoiesis. Patients on long-term treatment with NSAIDs, including ketorolac tromethamine, should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. NSAIDs inhibit platelet aggregation and have been shown to prolong <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> in some patients. Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible. Patients receiving ketorolac tromethamine who may be adversely affected by alterations in platelet function, such as those with <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorders</span> or patients receiving anticoagulants, should be carefully monitored.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s42"></a><a name="section-7.4"></a><p></p>
<h2>Preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>
</h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> may have aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. The use of aspirin in patients with aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> has been associated with severe <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> which can be fatal. Since cross reactivity, including <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, between aspirin and other nonsteroidal anti-inflammatory drugs has been reported in such aspirin-sensitive patients, ketorolac tromethamine should not be administered to patients with this form of aspirin sensitivity and should be used with caution in patients with preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s43"></a><a name="section-7.5"></a><p></p>
<h2>Information for Patients
</h2>
<p class="First">Ketorolac tromethamine is a potent NSAID and may cause serious side effects such as <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>, which may result in hospitalization and even fatal outcome.
</p>
<p>Physicians, when prescribing ketorolac tromethamine, should inform their patients or their guardians of the potential risks of ketorolac tromethamine treatment (see <span class="Bold"><a href="#s2">Boxed WARNING</a>,
</span><span class="Bold"><a href="#s25">WARNINGS</a></span><span class="Bold">,
</span><span class="Bold"><a href="#s38">PRECAUTIONS</a></span><span class="Bold">,</span> and <span class="Bold"><a href="#s68">ADVERSE REACTIONS</a></span> sections), instruct patients to seek medical advice if they develop treatment-related adverse events, and advise patients not to give oral ketorolac tromethamine to other family members and to discard any unused drug.
</p>
<p>Remember that the total combined duration of use of oral ketorolac tromethamine and IV or IM dosing of ketorolac tromethamine is not to exceed 5 days in adults. Ketorolac tromethamine is not indicated for use in pediatric patients.
</p>
<p>Patients should be informed of the following information before initiating therapy with an NSAID and periodically during the course of ongoing therapy. Patients should also be encouraged to read the NSAID Medication Guide that accompanies each prescription dispensed.
</p>
<ol class="Arabic">
<li>Advise patients to be alert for the symptoms of cardiovascular thrombotic events, including <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, or slurring of speech, and to report any of these symptoms to their healthcare provider immediately (see <span class="Bold"><a href="#s25">WARNINGS</a></span>).
</li>
<li>Ketorolac tromethamine, like other NSAIDs, can cause GI <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> and, rarely, serious GI side effects, such as <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, which may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious GI tract ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning symptoms, patients should be alert for the signs and symptoms of ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and should ask for medical advice when observing any indicative sign or symptoms including <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, and <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>. Patients should be apprised of the importance of this follow-up (see <span class="Bold"><a href="#s27">WARNINGS, Gastrointestinal Effects: Risk of Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation</a></span>).
</li>
<li>Ketorolac tromethamine, like other NSAIDs, can cause serious skin side effects such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, SJS, and TEN, which may result in hospitalizations and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> may occur without warning, patients should be alert for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> and <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, or other signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> such as <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and should ask for medical advice when observing any indicative signs or symptoms. Patients should be advised to stop the drug immediately if they develop any type of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and contact their physicians as soon as possible.
</li>
<li>Advise patients to be alert for the symptoms of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> including <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, unexplained <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and to contact their healthcare provider if such symptoms occur (see <span class="Bold"><a href="#s25">WARNINGS</a></span>).
</li>
<li>Patients should be informed of the warning signs and symptoms of hepatotoxicity (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, right upper quadrant <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, and “flu-like? symptoms). If these occur, patients should be instructed to stop therapy and seek immediate medical therapy.
</li>
<li>Patients should be informed of the signs of an <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face or throat). If these occur, patients should be instructed to seek immediate emergency help (see <span class="Bold"><a href="#s25">WARNINGS</a></span>).
</li>
<li>In late pregnancy, as with other NSAIDs, ketorolac tromethamine should be avoided because it will cause premature closure of the ductus arteriosus.
</li>
</ol>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="s44"></a><a name="section-7.6"></a><p></p>
<h2>Laboratory Tests
</h2>
<p class="First">Because serious GI tract ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning symptoms, physicians should monitor for signs or symptoms of GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Patients on long-term treatment with NSAIDs, should have their CBC and a chemistry profile checked periodically. If clinical signs and symptoms consistent with liver or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> develop, systemic manifestations occur (e.g., <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> etc.) or if abnormal liver tests persist or worsen, ketorolac tromethamine should be discontinued.
</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s45"></a><a name="section-7.7"></a><p></p>
<h2>Drug Interactions
</h2>
<p class="First">Ketorolac is highly bound to human plasma protein (mean 99.2%). There is no evidence in animal or human studies that ketorolac tromethamine induces or inhibits hepatic enzymes capable of metabolizing itself or other drugs.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s46"></a><a name="section-7.8"></a><p></p>
<h2>Warfarin, Digoxin, Salicylate, and Heparin
</h2>
<p class="First">The <span class="Italics">in vitro</span> binding of <span class="Bold Italics">warfarin</span> to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to 10 mcg/mL. Ketorolac does not alter <span class="Bold Italics">digoxin</span> protein binding. <span class="Italics">In vitro</span> studies indicate that, at therapeutic concentrations of <span class="Bold Italics">salicylate</span> (300 mcg/mL), the binding of ketorolac was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound ketorolac plasma levels. Therapeutic concentrations of <span class="Bold Italics">digoxin</span><span class="Bold Italics">,
</span><span class="Bold Italics">warfarin</span><span class="Bold Italics">,
</span><span class="Bold Italics">ibuprofen</span><span class="Bold Italics">,
</span><span class="Bold Italics">naproxen</span><span class="Bold Italics">,
</span><span class="Bold Italics">piroxicam</span><span class="Bold Italics">,
</span><span class="Bold Italics">acetaminophen</span><span class="Bold Italics">,
</span><span class="Bold Italics">phenytoin</span> and <span class="Bold Italics">tolbutamide</span> did not alter ketorolac tromethamine protein binding.
</p>
<p>In a study involving 12 adult volunteers, oral ketorolac tromethamine was coadministered with a single dose of 25 mg <span class="Bold Italics">warfarin</span>, causing no significant changes in pharmacokinetics or pharmacodynamics of warfarin. In another study, ketorolac tromethamine dosed IV or IM was given with two doses of 5,000 units of <span class="Bold Italics">heparin</span> to 11 healthy volunteers, resulting in a mean template <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> of 6.4 minutes (3.2 to 11.4 min) compared to a mean of 6 minutes (3.4 to 7.5 min) for heparin alone and 5.1 minutes (3.5 to 8.5 min) for placebo. Although these results do not indicate a significant interaction between ketorolac tromethamine and warfarin or heparin, the administration of ketorolac tromethamine to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored (see <span class="Bold"><a href="#s25">WARNINGS</a></span> and <span class="Bold"><a href="#s41">PRECAUTIONS: Hematological Effects</a></span>).
</p>
<p>The effects of warfarin and NSAIDs, in general, on GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> are synergistic, such that the users of both drugs together have a risk of serious GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> higher than the users of either drug alone.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s47"></a><a name="section-7.9"></a><p></p>
<h2>Aspirin
</h2>
<p class="First">When ketorolac tromethamine is administered with aspirin, its protein binding is reduced, although the clearance of free ketorolac tromethamine is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of ketorolac tromethamine and aspirin is not generally recommended because of the potential of increased adverse effects.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s48"></a><a name="section-7.10"></a><p></p>
<h2>Diuretics
</h2>
<p class="First">Clinical studies, as well as postmarketing observations, have shown that ketorolac tromethamine can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy with NSAIDs, the patient should be observed closely for signs of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> (see <span class="Bold"><a href="#s29">WARNINGS: Renal Effects</a></span>), as well as to assure diuretic efficacy.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s49"></a><a name="section-7.11"></a><p></p>
<h2>Probenecid
</h2>
<p class="First">Concomitant administration of oral ketorolac tromethamine and <span class="Bold Italics">probenecid</span> resulted in decreased clearance and volume of distribution of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 mcg/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours. Therefore, concomitant use of ketorolac tromethamine and probenecid is contraindicated.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s50"></a><a name="section-7.12"></a><p></p>
<h2>Lithium
</h2>
<p class="First">NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%. These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID. Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s51"></a><a name="section-7.13"></a><p></p>
<h2>Methotrexate
</h2>
<p class="First">NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices. This may indicate that they could enhance the toxicity of methotrexate. Caution should be used when NSAIDs are administered concomitantly with methotrexate.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s52"></a><a name="section-7.14"></a><p></p>
<h2>ACE Inhibitors/Angiotensin II Receptor Antagonists
</h2>
<p class="First">Concomitant use of <span class="Bold Italics">ACE inhibitors and/or angiotensin II receptor antagonists</span> may increase the risk of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, particularly in volume-depleted patients. Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors and/or angiotensin II receptor antagonists. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors and/or angiotensin II receptor antagonists.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s53"></a><a name="section-7.15"></a><p></p>
<h2>Antiepileptic Drugs
</h2>
<p class="First">Sporadic cases of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> have been reported during concomitant use of ketorolac tromethamine and <span class="Bold Italics">antiepileptic drugs</span> (phenytoin, carbamazepine).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s54"></a><a name="section-7.16"></a><p></p>
<h2>Psychoactive Drugs
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span> have been reported when ketorolac tromethamine was used in patients taking <span class="Bold Italics">psychoactive drugs</span> (fluoxetine, thiothixene, alprazolam).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s55"></a><a name="section-7.17"></a><p></p>
<h2>Pentoxifylline
</h2>
<p class="First">When ketorolac tromethamine is administered concurrently with <span class="Bold Italics">pentoxifylline</span>, there is an increased tendency to <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s56"></a><a name="section-7.18"></a><p></p>
<h2>Nondepolarizing Muscle Relaxants
</h2>
<p class="First">In postmarketing experience there have been reports of a possible interaction between ketorolac tromethamine IV/IM and <span class="Bold Italics">nondepolarizing muscle relaxants</span> that resulted in <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>. The concurrent use of ketorolac tromethamine with muscle relaxants has not been formally studied.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s57"></a><a name="section-7.19"></a><p></p>
<h2>Selective Serotonin Reuptake Inhibitors (SSRIs)
</h2>
<p class="First">There is an increased risk of <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> when <span class="Bold Italics">selective serotonin reuptake inhibitors</span> (SSRIs) are combined with NSAIDs. Caution should be used when NSAIDs are administered concomitantly with SSRIs.
</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s58"></a><a name="section-7.20"></a><p></p>
<h2>Carcinogenesis, mutagenesis, impairment of fertility
</h2>
<p class="First">An 18-month study in mice with oral doses of ketorolac tromethamine at 2 mg/kg/day (0.9 times the human systemic exposure at the recommended IM or IV dose of 30 mg qid, based on area-under-the-plasma-concentration curve [AUC]), and a 24-month study in rats at 5 mg/kg/day (0.5 times the human AUC) showed no evidence of tumorigenicity.
</p>
<p>Ketorolac tromethamine was not mutagenic in the Ames test, unscheduled DNA synthesis and repair, and in forward mutation assays. Ketorolac tromethamine did not cause chromosome breakage in the <span class="Italics">in vivo</span> mouse micronucleus assay. At 1590 mcg/mL and at higher concentrations, ketorolac tromethamine increased the incidence of chromosomal aberrations in Chinese hamster ovarian cells.
</p>
<p>Impairment of fertility did not occur in male or female rats at oral doses of 9 mg/kg (0.9 times the human AUC) and 16 mg/kg (1.6 times the human AUC) of ketorolac tromethamine, respectively.
</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s59"></a><a name="section-7.21"></a><p></p>
<h2>Pregnancy
</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s60"></a><a name="section-7.21.1"></a><p></p>
<h3>Teratogenic Effects
</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="s61"></a><a name="section-7.21.1.1"></a><p></p>
<h4>Pregnancy Category C
</h4>
<p class="First">Reproduction studies have been performed during organogenesis using daily oral doses of ketorolac tromethamine at 3.6 mg/kg (0.37 times the human AUC) in rabbits and at 10 mg/kg (1.0 times the human AUC) in rats. Results of these studies did not reveal evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> to the fetus. However, animal reproduction studies are not always predictive of human response.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="s62"></a><a name="section-7.21.2"></a><p></p>
<h3>Nonteratogenic Effects
</h3>
<p class="First">Because of the known effects of nonsteroidal anti-inflammatory drugs on the fetal cardiovascular system (closure of ductus arteriosus), use during pregnancy (particularly late pregnancy) should be avoided. Oral doses of ketorolac tromethamine at 1.5 mg/kg (0.14 times the human AUC), administered after gestation Day 17, caused dystocia and higher pup mortality in rats.
</p>
<p>There are no adequate and well-controlled studies of ketorolac tromethamine in pregnant women. Ketorolac tromethamine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="s63"></a><a name="section-7.22"></a><p></p>
<h2>Labor and Delivery
</h2>
<p class="First">The use of ketorolac tromethamine is contraindicated in labor and delivery because, through its prostaglandin synthesis inhibitory effect, it may adversely affect fetal circulation and inhibit uterine contractions, thus increasing the risk of <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine hemorrhage</span> (see <span class="Bold"><a href="#s24">CONTRAINDICATIONS</a></span>).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s64"></a><a name="section-7.23"></a><p></p>
<h2>Effects on Fertility
</h2>
<p class="First">The use of ketorolac tromethamine, as with any drug known to inhibit cyclooxygenase/ prostaglandin synthesis, may impair fertility and is not recommended in women attempting to conceive. In women who have difficulty conceiving or are undergoing investigation of <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span>, withdrawal of ketorolac tromethamine should be considered.
</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s65"></a><a name="section-7.24"></a><p></p>
<h2>Nursing Mothers
</h2>
<p class="First">Limited data from one published study that included 10 breastfeeding women 2 to 6 days postpartum showed low levels of ketorolac in breast milk and were undetectable (less than 5 ng/mL) in 4 of the patients. After a single administration of 10 mg of oral ketorolac tromethamine, the maximum milk concentration observed was 7.3 ng/mL, and the maximum milk-to-plasma ratio was 0.037. After 1 day of dosing (10 mg every 6 hours), the maximum milk concentration was 7.9 ng/mL, and the maximum milk-to-plasma ratio was 0.025.  Assuming a daily intake of 400 to 1,000 mL of human milk per day and a maternal body weight of 60 kg, the calculated maximum daily infant exposure was 0.00263 mg/kg/day, which is 0.4% of the maternal weight-adjusted dose.
</p>
<p>Exercise caution when ketorolac is administered to a nursing woman. Available information has not shown any specific adverse events in nursing infants; however, instruct patients to contact their infant's healthcare provider if they note any adverse events.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s66"></a><a name="section-7.25"></a><p></p>
<h2>Pediatric Use
</h2>
<p class="First">Ketorolac tromethamine is not indicated for use in pediatric patients. The safety and effectiveness of ketorolac tromethamine in pediatric patients below the age of 17 have not been established.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s67"></a><a name="section-7.26"></a><p></p>
<h2>Geriatric Use (≥65 years of age)
</h2>
<p class="First">Because ketorolac tromethamine may be cleared more slowly by the elderly (see <span class="Bold"><a href="#s4">CLINICAL PHARMACOLOGY</a></span>) who are also more sensitive to the dose-related adverse effects of NSAIDs (see <span class="Bold"><a href="#s27">WARNINGS: Gastrointestinal Effects: Risk of Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation</a></span>), extreme caution, reduced dosages (see <span class="Bold"><a href="#s73">DOSAGE AND ADMINISTRATION</a></span>), and careful clinical monitoring must be used when treating the elderly with ketorolac tromethamine.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s68"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS
</h1>
<p class="First">Adverse reaction rates increase with higher doses of ketorolac tromethamine. Practitioners should be alert for the severe complications of treatment with ketorolac tromethamine, such as G.I. ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and perforation, <span class="product-label-link" type="condition" conceptid="4002836" conceptname="Postoperative hemorrhage">postoperative bleeding</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, anaphylactic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> (see <span class="Bold"><a href="#s2">Boxed WARNING</a>,
</span><span class="Bold"><a href="#s25">WARNINGS</a></span><span class="Bold">,
</span><span class="Bold"><a href="#s38">PRECAUTIONS</a></span><span class="Bold">,</span> and <span class="Bold"><a href="#s73">DOSAGE AND ADMINISTRATION</a></span>). These NSAID-related complications can be serious in certain patients for whom ketorolac tromethamine is indicated, especially when the drug is used inappropriately.
</p>
<p>In patients taking ketorolac tromethamine or other NSAIDs in clinical trials, the most frequently reported adverse experiences in approximately 1% to 10% of patients are:
</p>
<p>Gastrointestinal (GI) experiences including:
</p>
<table width="100%">
<col align="left" width="33.333%">
<col align="left" width="33.333%">
<col align="left" width="33.333%">
<tbody class="Headless">
<tr class="First">
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>
</td>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>/<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>
</td>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>
</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>
</td>
<td align="left" valign="top">GI fullness
</td>
<td align="left" valign="top">GI <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> (gastric/duodenal)
</td>
</tr>
<tr>
<td align="left" valign="top">gross <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>/perforation
</td>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>
</td>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span><span class="Sup">*</span>
</td>
</tr>
<tr class="Last">
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>
</td>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>
</td>
<td align="left" valign="top"></td>
</tr>
</tbody>
</table>
<p>Other experiences:
</p>
<table width="100%">
<col align="left" width="33.333%">
<col align="left" width="33.333%">
<col align="left" width="33.333%">
<tfoot><tr class="First Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">*</span>Incidence greater than 10%
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td align="left" valign="top">abnormal renal function
</td>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>
</td>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>
</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>
</td>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>
</td>
<td align="left" valign="top">elevated liver enzymes 
</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span><span class="Sup">*</span>
</td>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>
</td>
<td align="left" valign="top">increased <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span>
</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">injection site pain</span>
</td>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>
</td>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span> 
</td>
</tr>
<tr class="Last">
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>
</td>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>
</td>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> 
</td>
</tr>
</tbody>
</table>
<p>Additional adverse experiences reported occasionally (&lt;1% in patients taking ketorolac tromethamine or other NSAIDs in clinical trials) include:
</p>
<p><span class="Bold">Body as a Whole</span></p>
<p><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>
</p>
<p><span class="Bold">Cardiovascular</span></p>
<p><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>
</p>
<p><span class="Bold">Dermatologic</span></p>
<p><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>
</p>
<p><span class="Bold">Gastrointestinal</span></p>
<p><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">excessive thirst</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span>
</p>
<p><span class="Bold">Hemic and Lymphatic</span></p>
<p><span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>
</p>
<p><span class="Bold">Metabolic and Nutritional</span></p>
<p>weight change
</p>
<p><span class="Bold">Nervous System</span></p>
<p><span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span>, <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">abnormal thinking</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesis</span>, inability to concentrate, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>
</p>
<p><span class="Bold">Reproductive, female</span></p>
<p><span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span>
</p>
<p><span class="Bold">Respiratory</span></p>
<p><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>
</p>
<p><span class="Bold">Special Senses</span></p>
<p>abnormal taste, <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span>
</p>
<p><span class="Bold">Urogenital</span></p>
<p><span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">increased urinary frequency</span>, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>/<span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>
</p>
<p>Other rarely observed reactions (reported from postmarketing experience in patients taking ketorolac tromethamine or other NSAIDs) are:
</p>
<p><span class="Bold">Body as a Whole</span></p>
<p><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> such as <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span>, <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>, <span class="product-label-link" type="condition" conceptid="4217627" conceptname="Edema of the tongue">tongue edema</span> (see <span class="Bold"><a href="#s25">WARNINGS</a></span>), <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>
</p>
<p><span class="Bold">Cardiovascular</span></p>
<p><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>
</p>
<p><span class="Bold">Dermatologic</span></p>
<p><span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, Lyell's syndrome, bullous reactions including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>
</p>
<p><span class="Bold">Gastrointestinal</span></p>
<p><span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>, <span class="product-label-link" type="condition" conceptid="4160872" conceptname="Recurrent aphthous ulcer">ulcerative stomatitis</span>, exacerbation of <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span> (<span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, Crohn's disease)
</p>
<p><span class="Bold">Hemic and Lymphatic</span></p>
<p><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, post operative <span class="product-label-link" type="condition" conceptid="4343234" conceptname="Wound hemorrhage">wound hemorrhage</span> (rarely requiring blood transfusion — see <span class="Bold"><a href="#s2">Boxed WARNING</a>, <a href="#s25">WARNINGS</a>, and <a href="#s38">PRECAUTIONS</a></span>)
</p>
<p><span class="Bold">Metabolic and Nutritional</span></p>
<p><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>
</p>
<p><span class="Bold">Nervous System</span></p>
<p><span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>
</p>
<p><span class="Bold">Respiratory</span></p>
<p><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>
</p>
<p><span class="Bold">Special Senses</span></p>
<p><span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>
</p>
<p><span class="Bold">Urogenital</span></p>
<p><span class="product-label-link" type="condition" conceptid="4090433" conceptname="Flank pain">flank pain</span> with or without <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> and/or <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, <span class="product-label-link" type="condition" conceptid="197253" conceptname="Hemolytic uremic syndrome">hemolytic uremic syndrome</span>
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s69"></a><a name="section-8.1"></a><p></p>
<h2>Postmarketing Surveillance Study
</h2>
<p class="First">A large postmarketing observational, nonrandomized study, involving approximately 10,000 patients receiving ketorolac tromethamine, demonstrated that the risk of clinically serious gastrointestinal (GI) <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> was dose-dependent (see <span class="Bold"><a href="#t3">Tables 3A</a> and <a href="#t3">3B</a></span>). This was particularly true in elderly patients who received an average daily dose greater than 60 mg/day of ketorolac tromethamine (see <span class="Bold"><a href="#t3">Table 3A</a></span>).
</p>
<a name="t3"></a><table width="100%">
<caption><span>Table 3 Incidence of Clinically Serious G.I. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> as Related to Age, Total Daily Dose, and History of G.I. Perforation, <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcer</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> (PUB) after up to 5 Days of Treatment with Ketorolac Tromethamine Injection
</span></caption>
<col align="left" width="20.500%">
<col align="left" width="17.380%">
<col align="left" width="17.380%">
<col align="left" width="22.660%">
<col align="left" width="22.080%">
<thead>
<tr class="First"><th class="Toprule" align="left" colspan="5" valign="top"><span class="Bold">A. Adult Patients without History of PUB</span></th></tr>
<tr><th class="Botrule" align="left" colspan="5" valign="top"><span class="Bold"> </span></th></tr>
<tr>
<th class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Age of Patients</span></th>
<th class="Botrule Rrule" align="center" colspan="4" valign="top"><span class="Bold">Total Daily Dose of Ketorolac Tromethamine Injection</span></th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule" align="center" valign="top"></th>
<th class="Botrule Rrule" align="center" valign="top"><span class="Bold">≤60 mg</span></th>
<th class="Botrule Rrule" align="center" valign="top"><span class="Bold">&gt;60 to 90 mg</span></th>
<th class="Botrule Rrule" align="center" valign="top"><span class="Bold">&gt;90 to 120 mg</span></th>
<th class="Botrule Rrule" align="center" valign="top"><span class="Bold">&gt;120 mg</span></th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" valign="top">&lt;65 years of age
</td>
<td class="Botrule Rrule" align="center" valign="top">0.4%
</td>
<td class="Botrule Rrule" align="center" valign="top">0.4%
</td>
<td class="Botrule Rrule" align="center" valign="top">0.9%
</td>
<td class="Botrule Rrule" align="center" valign="top">4.6%
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">≥65 years of age
</td>
<td class="Botrule Rrule" align="center" valign="top">1.2%
</td>
<td class="Botrule Rrule" align="center" valign="top">2.8%
</td>
<td class="Botrule Rrule" align="center" valign="top">2.2%
</td>
<td class="Botrule Rrule" align="center" valign="top">7.7%
</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold"> </span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr><td align="left" colspan="5" valign="top"><span class="Bold">B. Adult Patients with History of PUB</span></td></tr>
<tr>
<td class="Botrule" align="left" valign="top"><span class="Bold"> </span></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
<td class="Botrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Age of Patients</span></td>
<td class="Botrule Rrule" align="center" colspan="4" valign="top"><span class="Bold">Total Daily Dose of Ketorolac Tromethamine Injection</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">≤60 mg</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">&gt;60 to 90 mg</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">&gt;90 to 120 mg</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">&gt;120 mg</span></td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top">&lt;65 years of age
</td>
<td class="Botrule" align="center" valign="top">2.1%
</td>
<td class="Botrule" align="center" valign="top">4.6%
</td>
<td class="Botrule" align="center" valign="top">7.8%
</td>
<td class="Botrule Rrule" align="center" valign="top">15.4%
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left" valign="top">≥65 years of age
</td>
<td class="Botrule" align="center" valign="top">4.7%
</td>
<td class="Botrule" align="center" valign="top">3.7%
</td>
<td class="Botrule" align="center" valign="top">2.8%
</td>
<td class="Botrule Rrule" align="center" valign="top">25.0%
</td>
</tr>
</tbody>
</table>
<p><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Sagent Pharmaceuticals, Inc. at 1-866-625-1618 or FDA at 1-800-FDA-1088 or </span><span class="Bold Underline">www.fda.gov/medwatch</span><span class="Bold">.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s70"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s71"></a><a name="section-9.1"></a><p></p>
<h2>Symptoms and Signs
</h2>
<p class="First">Symptoms following acute NSAIDs <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> are usually limited to <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>, which are generally reversible with supportive care. <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal bleeding</span> can occur. <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> may occur, but are rare. <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> have been reported with therapeutic ingestion of NSAIDs, and may occur following an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s72"></a><a name="section-9.2"></a><p></p>
<h2>Treatment
</h2>
<p class="First">Patients should be managed by symptomatic and supportive care following a NSAIDs <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. There are no specific antidotes. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Emesis</span> and/or activated charcoal (60 g to 100 g in adults, 1 g/kg to 2 g/kg in children) and/or osmotic cathartic may be indicated in patients seen within 4 hours of ingestion with symptoms or following a large oral <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> (5 to 10 times the usual dose). Forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, alkalization of urine, hemodialysis or hemoperfusion may not be useful due to high protein binding.
</p>
<p>Single <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> of ketorolac tromethamine have been variously associated with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span>, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcers</span> and/or erosive <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span> and renal dysfunction which have resolved after discontinuation of dosing.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s73"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION
</h1>
<p class="First"><span class="Bold">Carefully consider the potential benefits and risks of ketorolac tromethamine injection and other treatment options before deciding to use ketorolac tromethamine. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals. In adults, the combined duration of use of IV or IM dosing of ketorolac tromethamine injection and oral ketorolac tromethamine is not to exceed 5 days. In adults, the use of oral ketorolac tromethamine is only indicated as continuation therapy to IV or IM dosing of ketorolac tromethamine injection. See package insert for ketorolac tromethamine tablets for transition from IV or IM dosing of ketorolac tromethamine (single- or multiple-dose) to multiple-dose oral ketorolac tromethamine.</span></p>
<p><span class="Bold">Note</span></p>
<p><span class="Bold">Oral formulation</span> should <span class="Bold">not</span> be given <span class="Bold">as an initial dose</span></p>
<p><span class="Bold">Use minimum effective dose</span> for the individual patient
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s74"></a><a name="section-10.1"></a><p></p>
<h2>Total duration of treatment in adult patients: 
</h2>
<p class="First">The combined duration of use of IV or IM dosing of ketorolac tromethamine and oral ketorolac tromethamine is not to exceed 5 days.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s75"></a><a name="section-10.2"></a><p></p>
<h2>Ketorolac Tromethamine Injection
</h2>
<p class="First">Ketorolac tromethamine injection may be used as a single or multiple dose on a regular or “prn? schedule for the management of moderately severe, <span class="product-label-link" type="condition" conceptid="433456" conceptname="Acute pain">acute pain</span> that requires <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> at the opioid level, usually in a postoperative setting. <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">Hypovolemia</span> should be corrected prior to the administration of ketorolac tromethamine (see <span class="Bold"><a href="#s29">WARNINGS:  Renal Effects</a></span>). Patients should be switched to alternative analgesics as soon as possible, but ketorolac tromethamine therapy is not to exceed 5 days.
</p>
<p>When administering ketorolac tromethamine injection, the IV bolus must be given over no less than 15 seconds. The IM administration should be given slowly and deeply into the muscle. The <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> begins in ~30 minutes with maximum effect in 1 to 2 hours after dosing IV or IM. Duration of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> is usually 4 to 6 hours.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s76"></a><a name="section-10.3"></a><p></p>
<h2>Single-Dose Treatment 
</h2>
<p class="First"><span class="Bold">The Following Regimen Should Be Limited To Single Administration Use Only </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s77"></a><a name="section-10.4"></a><p></p>
<h2>IM Dosing:
</h2>
<ul class="Disc">
<li>
<span class="Italics">Patients &lt; 65 years of age:</span> One dose of 60 mg.
</li>
<li>
<span class="Italics">Patients ≥ 65 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight:</span> One dose of 30 mg.
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s78"></a><a name="section-10.5"></a><p></p>
<h2>IV Dosing:
</h2>
<ul class="Disc">
<li>
<span class="Italics">Patients &lt; 65 years of age:</span> One dose of 30 mg.
</li>
<li>
<span class="Italics">Patients ≥ 65 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight:</span> One dose of 15 mg.
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s79"></a><a name="section-10.6"></a><p></p>
<h2>Multiple-Dose Treatment (IV or IM)
</h2>
<ul class="Disc">
<li>
<span class="Italics">Patients &lt; 65 years of age:</span> The recommended dose is 30 mg ketorolac tromethamine injection every 6 hours. The maximum daily dose for these populations should not exceed 120 mg.
</li>
<li>
<span class="Italics">For patients ≥ 65 years of age, renally impaired patients (see
</span><span class="Bold Italics"><a href="#s25">WARNINGS</a></span><span class="Italics">), and patients less than 50 kg (110 lbs):</span> The recommended dose is 15 mg ketorolac tromethamine injection every 6 hours. The maximum daily dose for these populations should not exceed 60 mg.
</li>
</ul>
<p class="First">For breakthrough <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, do not increase the dose or the frequency of ketorolac tromethamine. Consideration should be given to supplementing these regimens with low doses of opioids “prn? unless otherwise contraindicated.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s80"></a><a name="section-10.7"></a><p></p>
<h2>Pharmaceutical Information for Ketorolac Tromethamine Injection 
</h2>
<p class="First">Ketorolac tromethamine injection should not be mixed in a small volume (e.g., in a syringe) with morphine sulfate, meperidine hydrochloride, promethazine hydrochloride or hydroxyzine hydrochloride; this will result in precipitation of ketorolac from solution.
</p>
<p>NOTE: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s81"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED
</h1>
<p class="First">Ketorolac Tromethamine Injection, USP is supplied as follows:
</p>
<table width="100%">
<col align="left" width="18.533%">
<col align="left" width="54.767%">
<col align="left" width="26.700%">
<tfoot><tr class="First Last"><td align="left" colspan="3" valign="top"><p class="First Footnote">*For IM Use Only
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td align="left" valign="top"><span class="Bold">NDC</span></td>
<td align="left" valign="top"><span class="Bold">Ketorolac Tromethamine Injection, USP (15 mg per mL)</span></td>
<td align="left" valign="top"><span class="Bold">Package Factor</span></td>
</tr>
<tr>
<td align="left" valign="top">25021-700-01
</td>
<td align="left" valign="top">15 mg per mL Single-Dose Vial
</td>
<td align="left" valign="top">25 vials per carton
</td>
</tr>
<tr>
<td align="left" valign="top"> 
</td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold">NDC</span></td>
<td align="left" valign="top"><span class="Bold">Ketorolac Tromethamine Injection, USP (30 mg per mL)</span></td>
<td align="left" valign="top"><span class="Bold">Package Factor</span></td>
</tr>
<tr>
<td align="left" valign="top">25021-701-01
</td>
<td align="left" valign="top">30 mg per  mL Single-Dose Vial
</td>
<td align="left" valign="top">25 vials per carton
</td>
</tr>
<tr class="Last">
<td align="left" valign="top">*25021-701-02
</td>
<td align="left" valign="top">60 mg per 2 mL Single-Dose Vial
</td>
<td align="left" valign="top">25 vials per carton
</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="s82"></a><a name="section-11.1"></a><p></p>
<h2>Storage Conditions      
</h2>
<p class="First">Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]
</p>
<p><span class="Bold">Protect from light.</span> Retain in carton until time of use.<br><span class="Bold">Discard unused portion.</span></p>
<p><span class="Bold">Sterile, Nonpyrogenic, Preservative-free.</span></p>
<p><span class="Bold">The container closure is not made with natural rubber latex.</span></p>
<p>SAGENT™
</p>
<p>Mfd. for SAGENT Pharmaceuticals<br>Schaumburg, IL 60195 (USA)<br>Made in India<br>©2015 Sagent Pharmaceuticals, Inc.
</p>
<p>Revised: July 2015
</p>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="s83"></a><a name="section-12"></a><p></p>
<p class="First"><span class="Bold">Medication Guide</span></p>
<p><span class="Bold">for</span></p>
<p><span class="Bold">Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)</span></p>
<p><span class="Bold">Ketorolac Tromethamine Injection, USP</span></p>
<p><span class="Bold">What is the most important information I should know about medicines called Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)?</span></p>
<p><span class="Bold">NSAIDs can cause serious side effects, including:</span></p>
<ul class="Disc"><li>
<span class="Bold">Increased risk of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span> This risk may happen early in treatment and may increase:<ul class="Circle">
<li>with increasing doses of NSAIDs
</li>
<li>with longer use of NSAIDs
</li>
</ul>
</li></ul>
<p><span class="Bold">Do not take NSAIDs right before or after a heart surgery called a “coronary artery bypass graft (CABG).?</span></p>
<p><span class="Bold">Avoid taking NSAIDs after a recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>, unless your healthcare provider tells you to. You may have an increased risk of another <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> if you take NSAIDs after a recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>.</span></p>
<ul class="Disc"><li>
<span class="Bold">Increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, and tears (perforation) of the esophagus (tube leading from the mouth to the stomach), stomach and intestines:</span><ul class="Circle">
<li>anytime during use
</li>
<li>without warning symptoms
</li>
<li>that may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>
</li>
</ul>
<p class="First"><span class="Bold">The risk of getting an <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> increases with:</span></p>
<table width="100%">
<col align="left" width="50.400%">
<col align="left" width="49.600%">
<tbody class="Headless">
<tr class="First"><td align="left" colspan="2" valign="top"><ul class="Circle">
<li>past history of <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">stomach ulcers</span>, or stomach or intestinal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> with use of NSAIDs
</li>
<li>taking medicines called "corticosteroids", " anticoagulants", “SSRIs?, or “SNRIs?
</li>
</ul></td></tr>
<tr class="Last">
<td align="left" valign="top"><ul class="Circle">
<li>increasing doses of NSAIDs
</li>
<li>longer use of NSAIDs
</li>
<li>smoking
</li>
<li>drinking alcohol
</li>
</ul></td>
<td align="left" valign="top"><ul class="Circle">
<li>older age
</li>
<li>poor health
</li>
<li>advanced liver disease
</li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems
</li>
</ul></td>
</tr>
</tbody>
</table>
<p><span class="Bold">NSAIDs should only be used:</span></p>
<ul class="Circle">
<li>exactly as prescribed
</li>
<li>at the lowest dose possible for your treatment
</li>
<li>for the shortest time needed
</li>
</ul>
</li></ul>
<p><span class="Bold">What are NSAIDs?</span></p>
<p>NSAIDs are used to treat <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and heat (<span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>) from medical conditions such as different types of <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">menstrual cramps</span>, and other types of short-term <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.
</p>
<p><span class="Bold">Who should not take NSAIDs?</span></p>
<p><span class="Bold">Do not take NSAIDs:</span></p>
<ul class="Disc">
<li>if you have had an <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, or other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> with aspirin or any other NSAIDs.
</li>
<li>right before or after heart bypass surgery.
</li>
</ul>
<p><span class="Bold">Before taking NSAIDs, tell your healthcare provider about all of your medical conditions, including if you:</span></p>
<ul class="Disc">
<li>have liver or kidney problems
</li>
<li>have high blood pressure
</li>
<li>have <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>
</li>
<li>are pregnant or plan to become pregnant. Talk to your healthcare provider if you are considering taking NSAIDs during pregnancy. <span class="Bold">You should not take NSAIDs after 29 weeks of pregnancy.</span>
</li>
<li>are breastfeeding or plan to breastfeed.
</li>
</ul>
<p><span class="Bold">Tell your healthcare provider about all of the medicines you take, including prescription or over-the-counter medicines, vitamins or herbal supplements.</span> NSAIDs and some other medicines can interact with each other and cause serious side effects. <span class="Bold">Do not start taking any new medicine without talking to your healthcare provider first.</span></p>
<p><span class="Bold">What are the possible side effects of NSAIDs?</span></p>
<p><span class="Bold">NSAIDs can cause serious side effects, including:</span></p>
<p><span class="Bold">See “What is the most important information I should know about medicines called Non-steroidal Anti-Inflammatory Drugs (NSAIDs)?</span></p>
<ul class="Disc">
<li>new or worse high blood pressure
</li>
<li><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>
</li>
<li>liver problems including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>
</li>
<li>kidney problems including <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>
</li>
<li>low red blood cells (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>)
</li>
<li>life-threatening <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>
</li>
<li>life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>
</li>
<li>
<span class="Bold">Other side effects of NSAIDs include:</span> <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, gas, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.
</li>
</ul>
<p><span class="Bold">Get emergency help right away if you get any of the following symptoms:</span></p>
<table width="100%">
<col align="left" width="50.000%">
<col align="left" width="50.000%">
<tbody class="Headless"><tr class="First Last">
<td align="left" valign="top"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or trouble breathing
</li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in one part or side of your body
</li>
</ul></td>
<td align="left" valign="top"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face or throat
</li>
</ul></td>
</tr></tbody>
</table>
<p><span class="Bold">Stop taking your NSAID and call your healthcare provider right away if you get any of the following symptoms:</span></p>
<table width="100%">
<col align="left" width="50.000%">
<col align="left" width="50.000%">
<tbody class="Headless"><tr class="First Last">
<td align="left" valign="top"><ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>
</li>
<li>more tired or weaker than usual
</li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>
</li>
<li>your skin or eyes look yellow
</li>
<li><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span> or <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>
</li>
<li>flu-like symptoms
</li>
</ul></td>
<td align="left" valign="top"><ul class="Disc">
<li>vomit blood
</li>
<li>there is blood in your bowel movement or it is black and sticky like tar
</li>
<li>unusual <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the arms, legs, hands and feet
</li>
</ul></td>
</tr></tbody>
</table>
<p><span class="Bold">If you take too much of your NSAID, call your healthcare provider or get medical help right away.</span></p>
<p>These are not all the possible side effects of NSAIDs. For more information, ask your healthcare provider or pharmacist about NSAIDs.
</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
</p>
<p><span class="Bold">Other information about NSAIDs</span></p>
<ul class="Disc">
<li>Aspirin is an NSAID but it does not increase the chance of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>. Aspirin can cause <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the brain, stomach, and intestines. Aspirin can also cause <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in the stomach and intestines.
</li>
<li>Some NSAIDs are sold in lower doses without a prescription (over-the-counter). Talk to your healthcare provider before using over-the-counter NSAIDs for more than 10 days.
</li>
</ul>
<p><span class="Bold">General information about the safe and effective use of NSAIDs</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use NSAIDs for a condition for which it was not prescribed. Do not give NSAIDs to other people, even if they have the same symptoms that you have. It may harm them.
</p>
<p>If you would like more information about NSAIDs, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about NSAIDs that is written for health professionals.
</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.
</p>
<p>SAGENT™<br>Mfd. for SAGENT Pharmaceuticals<br>Schaumburg, IL 60195 (USA)<br>Made in India<br>©2015 Sagent Pharmaceuticals, Inc.
</p>
<p>Revised: July 2015
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s84"></a><a name="section-13"></a><p></p>
<p class="First">PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Vial Label
</p>
<p>NDC 25021-700-01
</p>
<p>Rx only
</p>
<p>Ketorolac Tromethamine Injection, USP
</p>
<p>15 mg per mL
</p>
<p>1 mL Single-Dose Vial
</p>
<p>For Intravenous or Intramuscular Use Only
</p>
<p>Protect from light.
</p>
<div class="Figure">
<a name="f02"></a><img alt="PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Vial Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=62591551-a644-4b2c-a0de-982e906fabc3&amp;name=ket06-0002-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s85"></a><a name="section-14"></a><p></p>
<p class="First">PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Vial Label
</p>
<p>NDC 25021-701-01
</p>
<p>Rx only
</p>
<p>Ketorolac Tromethamine Injection, USP
</p>
<p>30 mg per mL
</p>
<p>1 mL Single-Dose Vial
</p>
<p>For Intravenous or Intramuscular Use Only
</p>
<p>Protect from light.
</p>
<div class="Figure">
<a name="f03"></a><img alt="PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Vial Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=62591551-a644-4b2c-a0de-982e906fabc3&amp;name=ket06-0002-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s86"></a><a name="section-15"></a><p></p>
<p class="First">PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Vial Label
</p>
<p>NDC 25021-701-02
</p>
<p>Rx only
</p>
<p>Ketorolac Tromethamine Injection, USP
</p>
<p>60 mg per 2 mL (30 mg per mL)
</p>
<p>2 mL Single-Dose Vial
</p>
<p>FOR INTRAMUSCULAR USE ONLY
</p>
<p>Protect from light.
</p>
<div class="Figure">
<a name="f04"></a><img alt="PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – Vial Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=62591551-a644-4b2c-a0de-982e906fabc3&amp;name=ket06-0002-04.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>KETOROLAC TROMETHAMINE 		
					</strong><br><span class="contentTableReg">ketorolac tromethamine injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:25021-700</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ketorolac tromethamine</strong> (ketorolac) </td>
<td class="formItem">ketorolac tromethamine</td>
<td class="formItem">15 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:25021-700-01</td>
<td class="formItem">25  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091065</td>
<td class="formItem">09/05/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>KETOROLAC TROMETHAMINE 		
					</strong><br><span class="contentTableReg">ketorolac tromethamine injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:25021-701</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ketorolac tromethamine</strong> (ketorolac) </td>
<td class="formItem">ketorolac tromethamine</td>
<td class="formItem">30 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:25021-701-01</td>
<td class="formItem">25  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:25021-701-02</td>
<td class="formItem">25  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">2 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA091065</td>
<td class="formItem">09/05/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Sagent Pharmaceuticals
							(796852890)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 7/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>e649a366-3afa-40f1-bdb4-ed7fd0ba40c2</div>
<div>Set id: 62591551-a644-4b2c-a0de-982e906fabc3</div>
<div>Version: 6</div>
<div>Effective Time: 20150721</div>
</div>
</div> <div class="DistributorName">Sagent Pharmaceuticals</div></p>
</body></html>
